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Quinaldic acid formation requires an unusual rearrangement of the indole part of L-tryptophan to give a quinoline
ketone, further conversion of which into an enantiomerically pure S-alcohol is catalyzed by a stereospecific oxidore-
ductase. Duan et al. elucidate this chemistry and facilitate new thiopeptide generation, as shown by regiospecific fluo-
rination of thiostrepton with improved antibacterial activity.Supercharged Antibodies
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Mutation of surface residues to charged amino acids increases resistance
to aggregation and can enable reversible unfolding. Miklos et al. develop
a protocol that ‘‘supercharges’’ proteins while considering the energetic
implications of each mutation. Using a homology model, a single-chain
variable fragment antibody was designed that has a markedly enhanced
resistance to thermal inactivation and displays an unanticipated improve-
ment in affinity. Such supercharged antibodies should prove useful for
assays in resource-limited settings and for developing reagents with
improved shelf lives.Nerve Agent Detoxification
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Chemical warfare agents such as the G-type nerve gases (G-agents)
are highly toxic compounds. Currently available treatments of nerve agent intoxication are of limited effectiveness.
Using accelerated protein evolution techniques on the enzyme serum paraoxonase 1, Goldsmith et al. have developed
broad-spectrum variants of the enzyme that can rapidly degrade the four major G-agents. Their greatly enhanced
efficacy is coupled with a complete reversal of stereospecificity resulting in preference for the toxic enantiomers of
the chiral G-agents, rendering them highly suitable for both prophylaxis and postexposure treatment of nerve agent
intoxication.Specific Inhibitors of USP7/HAUSP
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The human USP7 deubiquitinating enzyme appears as novel strategic target for cancer therapy since it regulates many
proteins involved in cell cycle as well as tumor suppressors and oncogenes. Reverdy et al. identified small-molecule
inhibitors of USP7 and demonstrated USP7 inhibitor occupancy and selectivity in cancer cell lines. These active-
site-targeting inhibitors regulate the level of several USP7 substrates and thus recapitulated the USP7 knockdown
phenotype. These results provide proof of principle that USP7 inhibitors may be valuable therapeutics for cancer,
and the discovery of such molecules offers valuable tools for studying deubiquitination.Parasites in an Artificial Cell under Control
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One of the fundamental biological functions, translation-coupled replica-
tion of genetic information, was constructed fromwell-defined components
but ran into problems. Now, Bansho et al. report that the appearance of
parasitic replicators is a critical problem for the replication system and
successfully overcome this problem by encapsulating the reaction into
microcompartments. The results demonstrate that a mechanism for
repression of parasitic replicators is required to achieve a long-lasting
genome replication system, providing important insights for the possible
design of an artificial cell.Chemistry & Biology 19, April 20, 2012 ª2012 Elsevier Ltd All rights reserved vii
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Tissue infiltration of activated lymphocytes is a hallmark of transplant rejection and organ-specific autoimmune
diseases. DOCK2 plays a key role in migration and activation of lymphocytes, and its deficiency prevents rejection
of cardiac allografts and development of autoimmune diabetes in mouse models. Therefore, DOCK2 may serve as
a molecular target for controlling immune-related disorders. Here, Nishikimi et al. have identified CPYPP as
a small-molecule inhibitor of DOCK2. When lymphocytes were treated with CPYPP, both chemotactic response and
T cell activation were markedly suppressed. These findings provide basis for development of the DOCK2-targeting
immunosuppressant.viii Chemistry & Biology 19, April 20, 2012 ª2012Transporting Mycolic Acids
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Mycolic acids are key components of the cell wall of Mycobacterium
tuberculosis, the causative agent of tuberculosis (TB), and play an impor-
tant role in virulence. While the biosynthesis of these characteristic fatty
acids has been well studied, components of the transport machinery for
mycolic acids remained unknown. The study by Varela et al. demonstrates
that MmpL3, a large membrane-associated mycobacterial protein, is
involved in the transport of mycolic acids in the form of a glycolipid, treha-
losemonomycolate. The gene encodingMmpL3 is also essential for growth
highlighting its potential as a new drug target.
Phototswitchable LOV
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Photocontrol of functional peptides is a powerful tool for spatial and
temporal control of cell signaling events. Lungu et al. use genetically en-coded light-sensitive AsLOV2 domain to reversibly photomodulate the affinity of two peptides for their binding partners.
These peptideswere embedded into the Ja helix of the AsLOV2 domainwhilemaintaining AsLOV2 structure in the dark,
but allowing for binding to effector proteins in the light. Caged versions of the ipaA and SsrA peptides, LOV-ipaA and
LOV-SsrA, bind their targets with enhanced affinity in the light, thus enabling light-dependent photoactivatable gene
transcription in yeast.
Knocking Down HPV
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The human papillomavirus (HPV) oncoprotein E7, as well as other viral oncoproteins, bind to and inactivate the retino-
blastoma protein pRb. This inactivation can lead to a number of diseases, ranging from benign warts to cancers of the
cervix and other organs. Consequently, it is of interest to target this protein-protein interaction with small molecules.
Here, Fera et al. describe the development of a class of small molecule compounds that inhibit E7-pRb interaction
and are selectively cytotoxic in HPV-positive cells. These compounds provide a promising scaffold for the development
of therapies to treat HPV-mediated pathologies.Inhibiting c-Fes
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The c-Fes protein-tyrosine kinase regulates cellular differentiation, the
innate immune response, and vasculogenesis. Here Hellwig et al. report
the identification of kinase inhibitors with potent activity against c-Fes
both in vitro and in cell-based assays, one of which is the anaplastic
lymphoma kinase inhibitor TAE684. The authors solve a crystal structure
of TAE684 in complex with the c-Fes SH2-kinase domain unit and find
excellent shape complementarity with the ATP-binding pocket and a key
role for the gatekeeper methionine in inhibitor binding. TAE684 and other
nanomolar inhibitors identified in this study were used to establish a new
role for c-Fes in osteoclast differentiation from macrophages, identifying
Fes as a potential drug target in osteoporosis.Elsevier Ltd All rights reserved
